- call +1-201-465-4211
- email sales@mrinsights.biz
Amifostine (Ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.
Scope of the Report:
Amifostine is a pro-drug which is activated to the free thiol metabolite at the tissue site. The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.
Consumption of amifostine mainly concentrates in North America. In 2016, the region consumed 780 K Unit, holding about 52% market share globally. The follower is Asia-Pacific, with about 41% consumption share.
The market is relatively concentrated and there are just a few suppliers in the market, such as Clinigen Group, Sun Pharmaceutical, Merro Pharmaceutical and so on. Clinigen Group acquired the business from AstraZeneca in the year of 2014 and signed an agreement with Cumberland in the year of 2016. Under the agreement, Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Merro Pharmaceutical own the largest sales share in China.
Amifostine shows good effect in reducing harmful effects of cisplatin chemotherapy on kidneys in women treated for advanced ovarian cancer as well as relieving dry mouth problems (xerostomia) with head and neck cancer patients undergoing radiation treatment. It is estimated that the amifostine market will keep upward tendency and to be worthy of 49.99 million USD in 2023 globally.
The worldwide market for Amifostine is expected to grow at a CAGR of roughly 2.1% over the next five years, will reach 54 million US$ in 2024, from 48 million US$ in 2019, according to a new study.
This report focuses on the Amifostine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Clinigen Group
Sun Pharmaceutical
Taj Pharmaceuticals
Merro Pharmaceutical
Luye Pharma
Mingren Pharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
400mg/Dose
500mg/Dose
Market Segment by Applications, can be divided into
Head and Neck Cancer Adjuvant Therapy
Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Amifostine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Amifostine, with price, sales, revenue and global market share of Amifostine in 2017 and 2018.
Chapter 3, the Amifostine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Amifostine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Amifostine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Amifostine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Amifostine Introduction
1.2 Market Analysis by Type
1.2.1 400mg/Dose
1.2.2 500mg/Dose
1.3 Market Analysis by Applications
1.3.1 Head and Neck Cancer Adjuvant Therapy
1.3.2 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Clinigen Group
2.1.1 Business Overview
2.1.2 Amifostine Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Clinigen Group Amifostine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Sun Pharmaceutical
2.2.1 Business Overview
2.2.2 Amifostine Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sun Pharmaceutical Amifostine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 Taj Pharmaceuticals
2.3.1 Business Overview
2.3.2 Amifostine Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Taj Pharmaceuticals Amifostine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.4 Merro Pharmaceutical
2.4.1 Business Overview
2.4.2 Amifostine Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merro Pharmaceutical Amifostine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.5 Luye Pharma
2.5.1 Business Overview
2.5.2 Amifostine Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Luye Pharma Amifostine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.6 Mingren Pharma
2.6.1 Business Overview
2.6.2 Amifostine Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Mingren Pharma Amifostine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Amifostine Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global Amifostine Sales and Market Share by Manufacturer (2017-2018)
3.2 Global Amifostine Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 Amifostine Manufacturer Market Share in 2018
3.3.2 Top 6 Amifostine Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global Amifostine Market Analysis by Regions
4.1 Global Amifostine Sales, Revenue and Market Share by Regions
4.1.1 Global Amifostine Sales and Market Share by Regions (2014-2019)
4.1.2 Global Amifostine Revenue and Market Share by Regions (2014-2019)
4.2 North America Amifostine Sales and Growth Rate (2014-2019)
4.3 Europe Amifostine Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific Amifostine Sales and Growth Rate (2014-2019)
4.5 South America Amifostine Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa Amifostine Sales and Growth Rate (2014-2019)
5 North America Amifostine by Country
5.1 North America Amifostine Sales, Revenue and Market Share by Country
5.1.1 North America Amifostine Sales and Market Share by Country (2014-2019)
5.1.2 North America Amifostine Revenue and Market Share by Country (2014-2019)
5.2 United States Amifostine Sales and Growth Rate (2014-2019)
5.3 Canada Amifostine Sales and Growth Rate (2014-2019)
5.4 Mexico Amifostine Sales and Growth Rate (2014-2019)
6 Europe Amifostine by Country
6.1 Europe Amifostine Sales, Revenue and Market Share by Country
6.1.1 Europe Amifostine Sales and Market Share by Country (2014-2019)
6.1.2 Europe Amifostine Revenue and Market Share by Country (2014-2019)
6.2 Germany Amifostine Sales and Growth Rate (2014-2019)
6.3 UK Amifostine Sales and Growth Rate (2014-2019)
6.4 France Amifostine Sales and Growth Rate (2014-2019)
6.5 Russia Amifostine Sales and Growth Rate (2014-2019)
6.6 Italy Amifostine Sales and Growth Rate (2014-2019)
7 Asia-Pacific Amifostine by Country
7.1 Asia-Pacific Amifostine Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific Amifostine Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific Amifostine Revenue and Market Share by Country (2014-2019)
7.2 China Amifostine Sales and Growth Rate (2014-2019)
7.3 Japan Amifostine Sales and Growth Rate (2014-2019)
7.4 Korea Amifostine Sales and Growth Rate (2014-2019)
7.5 India Amifostine Sales and Growth Rate (2014-2019)
7.6 Southeast Asia Amifostine Sales and Growth Rate (2014-2019)
8 South America Amifostine by Country
8.1 South America Amifostine Sales, Revenue and Market Share by Country
8.1.1 South America Amifostine Sales and Market Share by Country (2014-2019)
8.1.2 South America Amifostine Revenue and Market Share by Country (2014-2019)
8.2 Brazil Amifostine Sales and Growth Rate (2014-2019)
8.3 Argentina Amifostine Sales and Growth Rate (2014-2019)
8.4 Colombia Amifostine Sales and Growth Rate (2014-2019)
9 Middle East and Africa Amifostine by Countries
9.1 Middle East and Africa Amifostine Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa Amifostine Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa Amifostine Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia Amifostine Sales and Growth Rate (2014-2019)
9.3 Turkey Amifostine Sales and Growth Rate (2014-2019)
9.4 Egypt Amifostine Sales and Growth Rate (2014-2019)
9.5 Nigeria Amifostine Sales and Growth Rate (2014-2019)
9.6 South Africa Amifostine Sales and Growth Rate (2014-2019)
10 Global Amifostine Market Segment by Type
10.1 Global Amifostine Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global Amifostine Sales and Market Share by Type (2014-2019)
10.1.2 Global Amifostine Revenue and Market Share by Type (2014-2019)
10.2 400mg/Dose Sales Growth and Price
10.2.1 Global 400mg/Dose Sales Growth (2014-2019)
10.2.2 Global 400mg/Dose Price (2014-2019)
10.3 500mg/Dose Sales Growth and Price
10.3.1 Global 500mg/Dose Sales Growth (2014-2019)
10.3.2 Global 500mg/Dose Price (2014-2019)
11 Global Amifostine Market Segment by Application
11.1 Global Amifostine Sales Market Share by Application (2014-2019)
11.2 Head and Neck Cancer Adjuvant Therapy Sales Growth (2014-2019)
11.3 Others Sales Growth (2014-2019)
12 Amifostine Market Forecast (2019-2024)
12.1 Global Amifostine Sales, Revenue and Growth Rate (2019-2024)
12.2 Amifostine Market Forecast by Regions (2019-2024)
12.2.1 North America Amifostine Market Forecast (2019-2024)
12.2.2 Europe Amifostine Market Forecast (2019-2024)
12.2.3 Asia-Pacific Amifostine Market Forecast (2019-2024)
12.2.4 South America Amifostine Market Forecast (2019-2024)
12.2.5 Middle East and Africa Amifostine Market Forecast (2019-2024)
12.3 Amifostine Market Forecast by Type (2019-2024)
12.3.1 Global Amifostine Sales Forecast by Type (2019-2024)
12.3.2 Global Amifostine Market Share Forecast by Type (2019-2024)
12.4 Amifostine Market Forecast by Application (2019-2024)
12.4.1 Global Amifostine Sales Forecast by Application (2019-2024)
12.4.2 Global Amifostine Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Amifostine Picture
Table Product Specifications of Amifostine
Figure Global Sales Market Share of Amifostine by Types in 2018
Table Amifostine Types for
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
